-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Recently, Darui Biomedical Technology (Shanghai) .
, L.
announced that it has obtained the global exclusive authorization for the chemical modification and delivery platform of Sanofi's small nucleic acid drug platform, as well as four undisclosed targe.
preclinical drug candidat.
It is understood that the technology platform provided by Sanofi is strategically helping Da Rui Bio to establish industry-leading advantages in oligonucleotide modification, delivery and nucleic acid biology in the rapidly growing fie.
This will enable Darui Bio to significantly expand and accelerate the application of its small nucleic acid drug pipeline in hepatic and non-liver therapeutic are.
In addition, Sanofi will gain exclusive rights to purchase neuro- and muscle-targeted drug candidates developed on the Darui platform outside of mainland China, Hong Kong, Taiwan and Macau (collectively, "Greater China.
In fact, in order to enhance the expansion of the research and development pipeline and accelerate the commercialization of products, the cooperation between pharmaceutical companies has become more and more frequent in the indust.
Since 2022, a large number of pharmaceutical companies have initiated cooperation in many fiel.
It should be noted that many of them have announced that they will cooperate with technology companies to accelerate innovation with the help of digital technologies and platfor.
For example, at the 5th Digital China Construction Summit held from July 23 to 24 this year, the signing ceremony of Yunnan Baiyao and Huawei's AI (artificial intelligence) drug research and development cooperation agreement was he.
Yunnan Baiyao will carry out extensive exchanges and cooperation with Huawei Technologies in the field of artificial intelligence drug research and development, explore the mechanism of joint scientific research and innovation, and expand the breadth and depth of cooperation between the two parties, including but not limited to large and small molecule design, related diseases, database development,e.
In June, Hisun Pharmaceutical and Yizhizhi and Jingtai Technology joined hands again to further expand the cooperation between the two parties in the field of chemical synthes.
It is reported that at the beginning of this year, the two parties launched the first chemical synthesis proje.
Jingtai Technology has an automated experimental technology platform and a compound management platform, which can provide flexible and intelligent chemical synthesis servic.
It will continue to help Hisun Pharmaceuticals explore drug synthesis routes and methods with higher efficiency and accelerate the process of drug research and developme.
In addition to domestic drugs At present, a large number of multinational pharmaceutical companies are also cooperating with relevant digital technology companies to build relevant domestic and foreign smart medical platforms and internal digital upgrades and innovatio.
For example, at the 4th China International Import Expo in 2021, Sanofi Pasteur and Olive Branch Health reached a strategic cooperation and decided to jointly explore and create a digital ecology of vaccin.
Specifically, it will mainly focus on improving the public's awareness and acceptance of vaccines; supporting the improvement of the digital service capabilities of the public health system, exploring innovative solutions for vaccination services such as unmanned vaccination cabins, and improving vaccine accessibili.
AstraZeneca has signed a 2022 strategic cooperation agreement with Dingdang Kuaiy.
The two parties announced that they will carry out in-depth cooperation relying on the advantages of Dingdang Kuaiyao's online and offline integrated "digital pharmacy" model, the digital capabilities of pharmaceutical services, AstraZeneca's dazzling drug research and development capabilities, and years of experience in the health busine.
In addition, Novartis Pharmaceuticals and Ark Jianke Group have also reached a strategic cooperati.
The two parties announced that they will carry out in-depth cooperation in drug services, disease management, doctor-patient education, e.
around the "Quanxin Wholeheartedness" project, and jointly explore the digital service model of "Internet + heart failure and chronic disease management" to provide patients with multi-faceted servic.
, refined health manageme.
From the above point of view, with the increasingly fierce competition in drug innovation, more hope has been placed on AI pharmaceuticals that can help new drug research and development, shorten the research and development cycle, improve the success rate of research and development, and reduce research and development cos.
In this context, the development of AI pharmaceuticals Inspur is expected to continue to be hot, and the investment and cooperation of pharmaceutical companies in this area may also continue to increa.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
, L.
announced that it has obtained the global exclusive authorization for the chemical modification and delivery platform of Sanofi's small nucleic acid drug platform, as well as four undisclosed targe.
preclinical drug candidat.
It is understood that the technology platform provided by Sanofi is strategically helping Da Rui Bio to establish industry-leading advantages in oligonucleotide modification, delivery and nucleic acid biology in the rapidly growing fie.
This will enable Darui Bio to significantly expand and accelerate the application of its small nucleic acid drug pipeline in hepatic and non-liver therapeutic are.
In addition, Sanofi will gain exclusive rights to purchase neuro- and muscle-targeted drug candidates developed on the Darui platform outside of mainland China, Hong Kong, Taiwan and Macau (collectively, "Greater China.
In fact, in order to enhance the expansion of the research and development pipeline and accelerate the commercialization of products, the cooperation between pharmaceutical companies has become more and more frequent in the indust.
Since 2022, a large number of pharmaceutical companies have initiated cooperation in many fiel.
It should be noted that many of them have announced that they will cooperate with technology companies to accelerate innovation with the help of digital technologies and platfor.
For example, at the 5th Digital China Construction Summit held from July 23 to 24 this year, the signing ceremony of Yunnan Baiyao and Huawei's AI (artificial intelligence) drug research and development cooperation agreement was he.
Yunnan Baiyao will carry out extensive exchanges and cooperation with Huawei Technologies in the field of artificial intelligence drug research and development, explore the mechanism of joint scientific research and innovation, and expand the breadth and depth of cooperation between the two parties, including but not limited to large and small molecule design, related diseases, database development,e.
In June, Hisun Pharmaceutical and Yizhizhi and Jingtai Technology joined hands again to further expand the cooperation between the two parties in the field of chemical synthes.
It is reported that at the beginning of this year, the two parties launched the first chemical synthesis proje.
Jingtai Technology has an automated experimental technology platform and a compound management platform, which can provide flexible and intelligent chemical synthesis servic.
It will continue to help Hisun Pharmaceuticals explore drug synthesis routes and methods with higher efficiency and accelerate the process of drug research and developme.
In addition to domestic drugs At present, a large number of multinational pharmaceutical companies are also cooperating with relevant digital technology companies to build relevant domestic and foreign smart medical platforms and internal digital upgrades and innovatio.
For example, at the 4th China International Import Expo in 2021, Sanofi Pasteur and Olive Branch Health reached a strategic cooperation and decided to jointly explore and create a digital ecology of vaccin.
Specifically, it will mainly focus on improving the public's awareness and acceptance of vaccines; supporting the improvement of the digital service capabilities of the public health system, exploring innovative solutions for vaccination services such as unmanned vaccination cabins, and improving vaccine accessibili.
AstraZeneca has signed a 2022 strategic cooperation agreement with Dingdang Kuaiy.
The two parties announced that they will carry out in-depth cooperation relying on the advantages of Dingdang Kuaiyao's online and offline integrated "digital pharmacy" model, the digital capabilities of pharmaceutical services, AstraZeneca's dazzling drug research and development capabilities, and years of experience in the health busine.
In addition, Novartis Pharmaceuticals and Ark Jianke Group have also reached a strategic cooperati.
The two parties announced that they will carry out in-depth cooperation in drug services, disease management, doctor-patient education, e.
around the "Quanxin Wholeheartedness" project, and jointly explore the digital service model of "Internet + heart failure and chronic disease management" to provide patients with multi-faceted servic.
, refined health manageme.
From the above point of view, with the increasingly fierce competition in drug innovation, more hope has been placed on AI pharmaceuticals that can help new drug research and development, shorten the research and development cycle, improve the success rate of research and development, and reduce research and development cos.
In this context, the development of AI pharmaceuticals Inspur is expected to continue to be hot, and the investment and cooperation of pharmaceutical companies in this area may also continue to increa.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
